Polymun was founded in 1992 by Prof. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. The last inspection by the Austrian regulatory authority AGES on behalf of EMA has taken place in June 2015, the last inspection by FDA in October 2013.
COMPETENCE & SERVICES
The two core competences of Polymun are the development and manufacture of biopharmaceuticals using mammalian cell technology as well as Polymun's innovative liposome technology and expertise. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.
Polymun employs a team of more than 70 dynamic and highly qualified scientists, technicians and support staff. 50 % hold an academic title, mostly in natural sciences such as biotechnology, biology or chemistry. About 40 % graduated from technical schools or colleges. Men and women are found equally in all positions. Polymun is also giving several of its employees the opportunity to perform their master or doctor theses within the scope of the company. With quality and reliability as a pre-requisite basis, innovation and creativity are strongly encouraged at Polymun.
Polymun has close contacts to the Department of Biotechnology at the University of Natural Resources and Life Sciences, Vienna. The fruitful scientific dialog and the broad methodological competence are of mutual benefit.
Polymun is partner in one project of the EU 7th Framework Program (Euripred) and one project of the EU Framework Program Horizon 2020 (EAVI2020).
Polymun′s customers and partners include renowned companies such as GlaxoSmithKline, Shire and Vogelbusch GmbH as well as non-profit organizations such as Imperial College London and the International AIDS Vaccine Initiative (IAVI).
MEET US AT
Controlled Release Society Annul Meeting
July 16-19, 2017
Dr. Andreas Wagner
ILS Liposome Advances and Liposome Research Days
Dr. Andreas Wagner
Dr. Charalampos Koutsoulas
Polymun started the development of a biosimilar rhFSH (follicle stimulating hormone) in 2006. Together with our license partner Finox AG, the drug product with the name Bemfola® was clinically tested successfully. Finox AG obtained market approval from EMA in April 2014. Since then, several other countries such as Australia, New Zealand and Israel have granted market approval for Bemfola®. Polymun remains the exclusive manufacturer of rhFSH as drug substance.